EF Hutton Initiates Coverage On Citius Pharma with Buy Rating, Announces Price Target of $6
Portfolio Pulse from Benzinga Newsdesk
EF Hutton has initiated coverage on Citius Pharma (NASDAQ:CTXR) with a Buy rating and a price target of $6, as announced by analyst Jason Kolbert.
July 15, 2024 | 1:44 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
EF Hutton has initiated coverage on Citius Pharma with a Buy rating and a price target of $6, indicating a positive outlook for the stock.
The initiation of coverage with a Buy rating and a specific price target of $6 by a reputable analyst can boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100